NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lantern Pharma's FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas
TL;DR
Lantern Pharma gains competitive edge with FDA orphan drug designation for LP-284, accelerating development for rare soft tissue sarcomas and expanding its oncology pipeline.
LP-284's orphan designation leverages its synthetic lethal mechanism targeting DNA repair deficiencies in soft tissue sarcomas, supporting an accelerated regulatory pathway during Phase 1 evaluation.
This designation advances precision therapies for rare cancer patients, potentially improving treatment outcomes and bringing hope to those with soft tissue sarcomas.
Lantern Pharma's AI-driven platform earned its sixth orphan designation, expanding LP-284 from blood cancers to solid tumors with a novel DNA-targeting approach.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma has received FDA Orphan Drug Designation for LP-284 for the treatment of soft tissue sarcomas.
The designation expands LP-284's application beyond hematologic malignancies into solid tumors, supports an accelerated regulatory pathway, and marks the third orphan designation for this specific program.
LP-284 uses a synthetic lethal mechanism that targets DNA repair deficiencies, which are common in adult soft tissue sarcomas.
LP-284 is currently in Phase 1 evaluation for B-cell non-Hodgkin lymphomas and is advancing development in additional rare cancer indications.
This is the sixth overall orphan drug designation across Lantern Pharma's clinical pipeline.
Lantern Pharma uses its proprietary RADR® AI platform that integrates hundreds of billions of data points with artificial intelligence and machine learning to identify biomarkers, predict drug response, and design clinical trials.
The company's clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations.
The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
BioMedWire is a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences sectors that provides wire solutions, article syndication, press release enhancement, social media distribution, and corporate communications solutions through the InvestorBrandNetwork.
Curated from InvestorBrandNetwork (IBN)
